CostrymCostrym
START
Giving failed biotechs a second chance

We turn failed clinical trials into approved drugs.

Your clinical trial failed. Run the asset through our AI rescue analysis to identify what went wrong and how to fix it, then tokenize the rescue into an on-chain SPV — letting investors fund the redesigned trial.

Get started
The math behind rescue
  • $2M+Cost per day
  • 90%Of trials fail
  • DaysDistress signal to redesigned trial
  • 6–8 wkFull rescue audit
  • 35%Of FDA landmarks involved a mid-course correction
03How We Diagnose It

Your trial failed for a reason. We find it in your data.

Here are the six ways trials get rescued:

Select a signal to see what Costrym does about it

02·The Scale— OVERVIEW

90% of trials fail. $50 billion in rescue data gets buried every year.

INDICATOR / 01
90%
Of trials fail
INDICATOR / 02
$50B
In rescue data buried — annually
INDICATOR / 03
300+
Phase 2/3 trials terminate per year
INDICATOR / 04
85%
Hide a buried responder subgroup

Inside 85% of failed trials: buried subpopulations where the drug actually worked.

Your molecules are in that graveyard. Your stock crashed 70%. Your board wants a fire sale. But inside your CTMS sits the survival signal — untouched, invisible, fixable.

— THE OTHER SIDE

$100M+ spent. Eight years gone. Stock craters overnight. Asset auctioned to big pharma for 10 cents on the dollar.

That's not a failure. That's a labeling problem.

— OUR APPROACH

We know how to look. We turn that graveyard data into approved drugs.

AI finds the signal. Blockchain funds the redesign.

04·Why Blockchain Works— COMPARISON

Blockchain funding turns failed trials into founder-owned approved drugs.

TRADITIONALWRONG INCENTIVES

The old way kills founders.

  • Cash gone — can't fund Phase 3 redesign from your balance sheet
  • Traditional VCs won't fund a 'rescue trial' — too risky, too unproven
  • Dilution kills equity; you lose control and upside
  • Pharma buys the asset for $10M after $100M spent. They own the drug.
— DEAD END
→ SHIFT TO
COSTRYMON-CHAIN SPV

Founders keep everything.

  • Institutional investors back the rescue specifically — not blind faith
  • Tokens = USDC payouts at milestones + buyout option at FDA approval
  • Your equity is never touched
  • After approval, buyout all tokens at pre-agreed price. You own 100%.
— OUTCOME

Smart contracts enforce transparency. Milestones auto-verify on blockchain. Investors see exactly what they funded and when they get paid.

Failed trial → 100% founder ownership.

05·The Team— LEADERSHIP

Built by people who've survived founder moments.

Domain experts in clinical development, regulatory affairs, AI infrastructure, and blockchain finance — combining technical depth with the operational rigor needed to navigate biotech rescue at scale.

Every person on this team has lived the consequence of a failed trial and knows what it takes to rebuild.

FOUR DISCIPLINES · ONE TEAM
DISCIPLINE / 01DEPTH 80
Clinical
Trial Design

Former VPs & Heads of Clinical Development

DISCIPLINE / 02DEPTH 70
Regulatory
Submissions

FDA submission veterans across rescue programs

DISCIPLINE / 03DEPTH 90
AI
Signal Recovery

Production ML on multi-modal trial data

DISCIPLINE / 04DEPTH 60
Blockchain
SPV Finance

On-chain SPV structuring & smart-contract finance

06·The Path to Ownership— TIMELINE

Three months to funding. Two years to approval. Lifetime of 100% ownership.

  1. 01Days 1–7Diagnosis
  2. 02Weeks 2–3Capital committed
  3. 03Months 1–24Trial executes
  4. 04Year 2+Founder-owned
STEP 01 / 04
7d
From data to diagnosis
AI Analysis·Days 1–7

Forensic AI on your complete trial dataset.

Costrym identifies what went wrong and where the rescue signal is — subgroup, endpoint, dosing. Outcome: a clear path forward, or a confident 'no rescue' answer. No guessing.

— THE RESULT

We don't take your equity. We don't take your control. We fund your rescue and give you full ownership on approval. From failed trial to founder-owned approved drug.

07·Why it works— EVIDENCE

The history of drug development is full of trials that failed and drugs that didn't.

Did the drug fail — or did the trial?

Not a consulting report. A rescue engine that never leaves.

The alternatives are a consulting firm that parachutes in four months too late to hand you a dossier of the data you already had — color-coded. A CRO too defensive to be honest. Or a board decision made on incomplete information that kills a program that didn't need to die.

Costrym is different because it never leaves. It is embedded in your trial systems from day one, reconstructing the real efficacy signal from within, and rebuilding the protocol around it when the failure pattern appears.

— CASE IN POINT
35%
OF FDA LANDMARKS INVOLVED A MID-COURSE CORRECTION
— Belimumab

Wrong patient population. Precision serology identified the responder subgroup. The trial was redesigned around them. Approved.

Clinical judgment from former VPs and Heads of Clinical Development. AI that runs continuously inside your stack so that judgment arrives in hours, not months.

Start with one program
08·Pricing— ENGAGEMENT

Outcome-based. Always.

ENGAGEMENT TERMS
#COSTRYM / 001
— MODEL
Outcome
BASED · ALWAYS

Compensation is tied to the value delivered — trial continuation, redesigned protocol running, or endpoint achieved.

— INCLUDED
  • No retainers$0
  • No asset takebacks$0
  • No equity dilution$0
  • No competitive conflict$0
TOTAL UPFRONT$0
09·Get started— CONTACT

Your next approved drug is already in your active portfolio.

costrym — intake
$echo "send name + program"
→we're inside the data before the next board meeting
$ reply --to=costrym@budera.app

Start with one program. Send a name and a program. We'll send you a link to book time with our team.

Get startedcostrym@budera.app